Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity

被引：0

作者：

Muik, Alexander ^{[1
]}

Altintas, Isil ^{[2
]}

Gieseke, Friederike ^{[1
]}

Salcedo, Theodora ^{[2
]}

Burm, Saskia ^{[2
]}

Diken, Mustafa ^{[1
]}

Grunwitz, Christian ^{[1
]}

Schuurhuis, Danita ^{[2
]}

Kreiter, Sebastian ^{[1
]}

Satijn, David ^{[2
]}

Tureci, Ozlem ^{[1
]}

Breij, Esther ^{[2
]}

Sahin, Ugur ^{[1
]}

Jure-Kunkel, Maria ^{[2
]}

机构：

[1] BioNTech SE, Mainz, Germany

[2] Genmab, Utrecht, Netherlands

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P609

引用

页数：2

共 50 条

[31] LIGHT (TNFSF14) CO-STIMULATION ENHANCES MYELOID CELL ACTIVATION AND ANTI-TUMOR IMMUNITY IN THE SETTING OF PD-1 AND TIGIT CHECKPOINT BLOCKADE
Fromm, George
Yoo, Kyung Jin
Johannes, Kellsey
Shuptrine, Casey
Opheim, Zach
Patel, Arpita
Andreasen, Haley
Miriyala, Jaya
De Silva, Suresh
Schreiber, Taylor
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A615 - A615
[32] QL301, a PD-L1 dependent 4-1BB agonist with enhanced preclinical anti-tumor efficacy and minimal liver toxicity
Gu, Shenda
Tang, Irene
Mihardja, Shirley
Prior, Wei Wei
Tran, Hieu V.
Chan, Allan
McClain, Anna
Kurtzman, Aaron
Chen, Shihao
Luo, Youguang
Kang, Xiaoyan
Wu, Xiaoran
Zheng, Qingmei
Jia, Guodong
CANCER RESEARCH, 2022, 82 (12)
[33] FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies
Sam, Johannes
Claus, Christina
Ferrara, Claudia
Lang, Sabine
Nicolini, Valeria
Colombetti, Sara
Teichgraber, Volker
Evers, Stefan
Bacac, Marina
Umana, Pablo
Klein, Christian
CANCER RESEARCH, 2018, 78 (13)
[34] The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies
Jensen, Benjamin A. H.
Pedersen, Sara R.
Christensen, Jan P.
Thomsen, Allan R.
PLOS ONE, 2013, 8 (06):
[35] An Fc-competent bispecific antibody targeting PD-L1 and TIGIT induces strong immune responses and potent anti-tumor efficacy.
Dai, Shuang
Huang, Weifeng
Yuan, Zhijun
Peng, Shaogang
Si, Jiayi
Wang, Chao
Yan, Yao
Miao, Xiaoniu
Xu, Yingda
Sun, Joanne
Liu, Xiaolin
Tsun, Andy
Zhai, Tianhang
CANCER RESEARCH, 2022, 82 (12)
[36] PD-L1 Checkpoint Blockade Using a Single-Chain Variable Fragment Targeting PD-L1 Delivered by Retroviral Replicating Vector Enhances Anti-Tumor Effect in Cancer Models
Lin, Amy H.
Yagiz, Kader
Hofacre, Andrew
Munday, Anthony W.
Espinoza, Fernando Lopez
Mendoza, Daniel
Burrascano, Cynthia
Gruber, Harry E.
Mitchell, Leah A.
Jolly, Douglas J.
MOLECULAR THERAPY, 2018, 26 (05) : 54 - 54
[37] LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model.
Huang, Xiao
Sun, Jianming
Qin, Yurong
Lin, Huan
Guan, Jing
Lai, Shoupeng
Kang, Xiaoqiang
Ling, Hong
CANCER RESEARCH, 2021, 81 (13)
[38] The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China A bibliometrics study
Zhao, Xiaoqin
He, Liangmei
Mao, Kaiyun
Chen, Daming
Jiang, Hongbo
Liu, Zhiping
MEDICINE, 2018, 97 (15)
[39] Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
Yang, Rui
He, Qing
Zhou, Hui
Gong, Cheng
Wang, Xing
Song, Xingpan
Luo, Fang
Lei, Yang
Ni, Qian
Wang, Zili
Xu, Shasha
Xue, Yan
Zhang, Man
Wen, Haimei
Fang, Lijuan
Zeng, Liang
Yan, Yongxiang
Shi, Jian
Zhang, Jing
Yi, Jizu
Zhou, Pengfei
FRONTIERS IN IMMUNOLOGY, 2022, 13
[40] The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 x αPD-L1 bispecific antibody-armed T cells
Cho, Jaewon
Tae, Nara
Song, Yujeong
Kim, Chae-Won
Lee, Seung-Joo
Ahn, Jae-Hee
Lee, Kwang-Ho
Lee, Byung-Hyun
Kim, Byung Soo
Chang, Sun-Young
Kim, Dae Hee
Ko, Hyun-Jeong
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)

← 1 2 3 4 5 →